Last reviewed · How we verify

NCT05403970

Correlation of Various Laboratory Parameters With Outcome in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage - Prospective Case Series

Status unknown Last updated 1 July 2022
What this trial tests

trial in Subarachnoid Hemorrhage in 300 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorUniversity of Debrecen
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date1 June 2022
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across Hungary

Conditions studied

Sponsor

University of Debrecen

Who can join

18 and older, any sex, with Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective study, the investigators aim to investigate the effect of the following three factors on the development of vasospasm and patient outcome: (1.) the role of anemia; (2.) the role of plasma fibrinolytic activity; (3.) the role of vitamin D. The investigators include patients admitted to the Neurosurgical Intensive Care Unit of the Clinical Center of the University of Debrecen with the diagnosis of subarachnoid hemorrhage (SAH). Patients are treated according to international guidelines. As part of the study protocol the following investigations are performed: • Hemoglobin level measurement: on the day of admission and day 3-4-7 and 14 after hemorrhage •Modified clot lysis assay (mCLA): on the day of admission and day 7 after hemorrhage •25-hydroxy vitamin-D level measurement: on the day of admission •Transcranial color-coded duplex sonography (detecting vasospasm): on daily basis. •30 day follow-up: mortality, Glasgow Outcome Scale (GOS), Karnofsky score, Barthel score •90 day follow-up: mortality, Glasgow Outcome Scale , Karnofsky score, Barthel score. Laboratory test results are correlated with (a) the development of vasospasm; (b) with 30 and 90 day outcome. Perspectives of the planned study: Considering the currently available therapeutic range for patients with SAH, results of the present study may provide a basis for designing further randomized, prospective trials to investigate the effect of treating anemia, anticoagulation and vitamin-D supplementation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Correlation of Inflammatory Parameters with the Development of Cerebral Vasospasm, Takotsubo Cardiomyopathy, and Functional Outcome after Spontaneous Subarachnoid Hemorrhage.
    Szántó D, Luterán P, Kóti N, Siró P, et al · · 2024 · cited 2× · PMID 38610720 · DOI 10.3390/jcm13071955
  2. Impact of vitamin D deficiency on clinical outcomes in non-traumatic subarachnoid hemorrhage: A single-center prospective cohort study.
    Szántó D, Fülesdi B, Simon L, Novák L, et al · · 2026 · PMID 41639253 · DOI 10.1038/s41598-026-38728-9

Verify or expand the search:

Other recruiting trials for Subarachnoid Hemorrhage

Currently open trials in the same condition.

Other University of Debrecen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05403970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing